phenotype nor a clear-cut genetic background has been observed in these studies. Syampurnawati et al.
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The runt-related transcription factor 1 (RUNX1) encodes for an a-subunit of the core-binding factor and is known as the key regulator in myeloid cells. Heterozygous germline mutations in RUNX1 were identified as a causative genetic alteration leading to a familial platelet disorder with propensity to myeloid malignancies (FPD/MM). For the development of overt leukemia, secondary alterations are required. 1 To discuss the potential use of FPD/MM as a multistep model for leukemic transformation in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), we report here on a female index patient and her father, who both developed MDS-related AML (MDR-AML) with differing clinical course caused by a heterozygous germline mutation in RUNX1 and different secondary chromosomal aberrations.
The 13-year-old female index patient (III:3, Figure 1a ) was diagnosed with MDR-AML after a brief history of anemia. Subsequently, she underwent hematopoietic stem cell transplantation (HSCT) from an unrelated donor. Sibling donor HSCT was avoided as MDR-AML was diagnosed in her 47-yearold father 6 months earlier (II:6, Figure 1a) . The twin brother, one younger and one older brother of the index patient and their mother are clinically healthy. No history of thrombocytopenia or platelet defects was reported in the family.
Analysis of RUNX1 identified the heterozygous germline mutation c.520C4T, p.Arg174X in the index patient and her father (Figure 1b) . The frameshift mutation with a predicted dominant negative effect 2 was earlier found in another family with FPD/MM and a sporadic case of atypical CML with acquired trisomy 21. 3, 4 Chromosome analysis of bone marrow cells from our index patient showed a deletion of 5q (del(5q)) and a structural aberration of 2q. Array-based comparative genomic hybridization (aCGH) confirmed the del(5q) and pointed to an unbalanced translocation t(2;6)(q36;q23) (Figures 1c and d) , finally confirmed by fluorescence in situ hybridization using a specific probe for v-myb myeloblastosis viral oncogene homolog, avian (MYB) (Figure 1e ). In contrast, the only aberration identified in bone marrow cells of the diseased father was a loss of the Y chromosome (-Y) (Figure 1c ). Whereas -Y is a typical chromosome aberration of adult MDS associated with a good prognosis, del(5q) is rarely seen in childhood MDS and usually occurs within complex clones associated with a more unfavorable prognosis. In our index patient, the gain of 6q led to an additional copy of the proto-oncogene MYB, an essential transcription factor in hematopoietic cells. 5 Genetic alterations involving MYB, including locus duplication, were earlier found in a subset of T-acute lymphoblastic leukemia. 6 In addition, Zhao et al. 7 recently reported on a negative feedback loop between MYB and miR-15a located in 13q14, a region frequently deleted in myeloid and lymphocytic leukemia. Thus, MYB is an interesting candidate for leukemic transformation that may co-operate with heterozygous germline mutations in RUNX1 and del(5q). Although heterozygous mutations in RUNX1 are not sufficient for leukemogenesis, 1,2 somatically acquired secondary events may promote transformation leading to overt MDS and AML. As seen in the reported family, recruitment of different secondary alterations may partially explain the variable penetrance and clinical heterogeneity seen in FPD/MM. Cytogenetic investigations of leukemia patients with FPD/MM displayed chromosomal aberrations that frequently occur in sporadic MDS/AML, and vice versa, RUNX1 mutations were seen in sporadic MDS/ AML. 1 Consequently, rare FPD/MM-related myeloid malignancies may serve as a model for multistep leukemogenesis in MDS/AML 8 and, as illustrated here, aCGH may help to identify candidate genes involved in malignant transformation in familial and sporadic myeloid malignancies.
The disappointing results in the treatment of primary myelofibrosis (PM) with interferon, reviewed by Kiladjian et al.,
1 with no objective responses in 84 PM patients, have prompted us to submit this letter regarding our success of using low-dose interferon in treating early-stage PM. In this study, we sought to avoid the progression of disease in patients who had early-stage disease. Those treated with interferon were good-risk patients, with relatively good blood cell counts and minimal to moderate bone-marrow fibrosis. We report here that early treatment in this good-risk group showed an improvement in bone-marrow fibrosis and in the control of splenomegaly. The use of interferon is based on its effects on megakaryopoiesis, which include decreasing megakaryocyte density and size, 2 inhibiting thrombopoietin-induced signaling, 3 suppressing the expression of transcription factors 4 and reducing levels of platelet-derived growth factor, 5 all of which play a major role in the pathogenesis of myelofibrosis. 1 The diagnosis of PM was established clinically, hematologically and by bone-marrow trephine biopsy, consistent with published criteria. [4] [5] [6] Pretreatment evaluation included history, physical examination, complete blood cell count and differential CD34 count, BCR-ABL and JAK2 V617F allele burden determinations, serum chemistries and thyroid function tests. Spleen size was categorized as not enlarged, slightly enlarged (1-3 cm), moderately (4-9 cm) or markedly enlarged (49 cm), as palpated below the costal margin in the mid-clavicular line. Exclusion criteria included marrow findings as below, and the usual contraindications to recombinant interferon alpha-2b (rIFNa). 7 The bone-marrow biopsy specimens, routinely processed, were stained with hematoxylin-eosin and giemsa, and for reticulin and collagen, quantified by the method of Manoharan, et al. 6 Excluded patients showed advanced fibro-osteosclerosis, grade 3 or 4 reticulin deposition, coarse bundles of collagen fibers 6 and no residual hematopoiesis. Patients considered for study required
